H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Sensorion SAS on June 30 and set a price target of €3.00.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Joseph Pantginis has given his Buy rating due to a combination of factors, primarily centered around the promising early data from Sensorion’s Phase 1/2 Audiogene study with SENS-501. The study, which focuses on infants and toddlers with profound hearing loss due to mutations in the otoferlin gene, has shown encouraging results from the low dose cohort.
Key highlights include the safety and tolerability of SENS-501 in the initial patient group, with one patient demonstrating significant improvements in hearing responses. This includes positive auditory brainstem response (ABR) at two frequencies and improved hearing levels across speech frequencies, as measured by pure-tone audiometry (PTA). Additionally, parental feedback indicated meaningful improvements in the child’s responses to sounds, reflected in a substantial increase in the IT-MAIS score, suggesting a potential breakthrough in addressing profound hearing loss.
In another report released on July 1, Chardan Capital also initiated coverage with a Buy rating on the stock with a €1.00 price target.